Xiangrong Biotech Submits Protocol Amendment for Phase III Clinical Trial of Adipose-Derived Stem Cell Therapy ELIXCYTE-OA for Knee Osteoarthritis to US FDA
Xiangrong Biotech has submitted a protocol amendment to the U.S. FDA for its allogeneic adipose-deri… · 2026-07-21